Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444952 | 1.00 | ALDH1A1 (0.53) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL7279383 | 0.87 | FOLH1 (0.47) | FOLH1MME | |
| SCHEMBL6824840 | 0.87 | PLA2G2A (0.55) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL7279380 | 0.87 | FOLH1 (0.47) | FOLH1MME | |
| SCHEMBL2455888 | 0.87 | PLA2G2A (0.55) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL1068731 | 0.87 | PLA2G2A (0.55) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| Water SCHEMBL4794958 | 0.85 | PLA2G2A (0.54) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL30174895 | 0.85 | PLA2G2A (0.57) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL16124610 | 0.85 | PLA2G2A (0.57) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| Water SCHEMBL27304038 | 0.85 | PLA2G2A (0.54) | ALDH1A1FOLH1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0839798-A2 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5670675-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| US-5545750-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-5142056-A | Human immunodeficiency virus protease inhibitor | ABBOTT LABORATORIES (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0415981-A4 | RETROVIRAL PROTEASE INHIBITORS | — | 1991-10-09 | — | — | EP | disclosed |
| EP-0415981-A1 | RETROVIRAL PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0402646-A1 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
| WO-1989010752-A1 | RETROVIRAL PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | ALDH1A1 889/4885FOLH1 409/4885MEN1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.